Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,120 shares of the medical research company’s stock after selling 4,645 shares during the period. Amgen makes up 1.1% of Meyer Handelman Co.’s holdings, making the stock its 28th biggest holding. Meyer Handelman Co.’s holdings in Amgen were worth $40,238,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. TCW Group Inc. grew its position in Amgen by 12.8% in the second quarter. TCW Group Inc. now owns 28,369 shares of the medical research company’s stock worth $10,273,000 after acquiring an additional 3,222 shares during the period. Fulton Breakefield Broenniman LLC raised its position in Amgen by 6.1% in the second quarter. Fulton Breakefield Broenniman LLC now owns 6,136 shares of the medical research company’s stock valued at $2,222,000 after purchasing an additional 351 shares during the period. BIP Wealth LLC raised its position in Amgen by 6.3% in the second quarter. BIP Wealth LLC now owns 9,380 shares of the medical research company’s stock valued at $3,397,000 after purchasing an additional 556 shares during the period. Trifecta Capital Advisors LLC lifted its stake in shares of Amgen by 3.2% in the 2nd quarter. Trifecta Capital Advisors LLC now owns 16,502 shares of the medical research company’s stock valued at $5,976,000 after purchasing an additional 510 shares during the last quarter. Finally, Elyxium Wealth LLC lifted its stake in shares of Amgen by 607.3% in the 2nd quarter. Elyxium Wealth LLC now owns 14,252 shares of the medical research company’s stock valued at $5,161,000 after purchasing an additional 12,237 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $415.21 on Friday. The business has a 50-day moving average of $370.57 and a 200 day moving average of $358.93. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $421.79. The stock has a market capitalization of $224.47 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AMGN. Robert W. Baird raised their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Bank of America upped their target price on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Truist Financial boosted their price target on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $372.39.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.